Track topics on Twitter Track topics that are important to you
Nivolumab did not extend progression-free survival over chemotherapy in the first-line setting in patients with PD-L1–positive advanced non–small-cell lung cancer, according to results of an open-label phase III trial.
Original Article: First-Line Nivolumab in Advanced Lung Cancer Fails to Improve OutcomesNEXT ARTICLE
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...